Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.

Date publication

mai 2017

Journal

The lancet. Gastroenterology & hepatology

Auteurs

Membres identifiés du Cancéropôle Est :
Mme MEURISSE Aurélia

Tous les auteurs :
Bachet JB, Hammel P, Desramé J, Meurisse A, Chibaudel B, André T, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Meyer VG, Taieb J, Volet J, Monier A, Bonnetain F, Louvet C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28397697

Résumé

Nab-paclitaxel plus gemcitabine has become a standard treatment regimen in patients with metastatic pancreatic adenocarcinoma; however, retrospective data suggest that gemcitabine might be inefficient in 50-60% of patients and thus not an optimum regimen in combination with nab-paclitaxel. We did a phase 2 trial to assess the activity and safety of a new regimen of nab-paclitaxel plus simplified leucovorin and fluorouracil.

Mots clés

Adenocarcinoma, drug therapy, Aged, Aged, 80 and over, Albumins, adverse effects, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Deoxycytidine, adverse effects, Female, Fluorouracil, adverse effects, Humans, Intention to Treat Analysis, Leucovorin, adverse effects, Male, Middle Aged, Neoplasm Metastasis, Paclitaxel, adverse effects, Pancreatic Neoplasms, drug therapy, Survival Analysis, Gemcitabine

Référence

Lancet Gastroenterol Hepatol. 2017 05;2(5):337-346